FOXO4-DRI
Senolytic Peptide · p53-FOXO4 Disruptor
FOXO4-DRI is a senolytic peptide designed to selectively eliminate senescent 'zombie' cells that accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive. The 'DRI' modification (D-retro-inverso) uses reversed D-amino acids to increase potency and stability. Preclinical research shows restoration of fur density, fitness, and organ function in aged mice.
Overview
FOXO4-DRI is a senolytic peptide designed to selectively eliminate senescent 'zombie' cells that accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive. The 'DRI' modification (D-retro-inverso) uses reversed D-amino acids to increase potency and stability. Preclinical research shows restoration of fur density, fitness, and organ function in aged mice.
FOXO4-DRI competes with FOXO4 for binding to p53, disrupting their protective interaction in senescent cells. This causes p53 to be excluded from the nucleus and triggers cell-intrinsic apoptosis (programmed cell death). Critically, this mechanism is highly selective: the FOXO4-p53 interaction is a specific vulnerability of senescent cells, while FOXO4 is minimally expressed in healthy tissues, leaving functional cells largely unharmed.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Selectively induces apoptosis in senescent cells while sparing healthy tissue.
Restores tissue homeostasis and function in naturally aged animal models.
Improved fitness, mobility, and physical appearance in aged mice.
Restored renal function in aged and fast-aging mouse models.
Improved testicular microenvironment and testosterone secretion in aged mice.
Removes senescent chondrocytes, potentially benefiting joint health.
Neutralizes doxorubicin-induced chemotoxicity by clearing treatment-induced senescent cells.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- D-retro-inverso peptide
- Chain length
- 45 residues
- Molecular weight
- 4800 Da
- Typical dose
- 25-33 mg per injection (based on mouse study 5 mg/kg)
- Frequency
- 3 doses total, administered every other day (Day 1, 3, 5)
- Cycle length
- 6 days (3 doses total = 75-100 mg per treatment cycle)
- Storage
- Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use immediately or within short term; avoid freeze-thaw cycles
Molecular data
- Type
- D-retro-inverso peptide
- Molecular weight
- 4800 Da
- Chain length
- 45 residues
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Standard senolytic protocol | SubQ or IV | 25-33 mg | 3 doses, every other day (6 days total) |
| Mouse study equivalent | IP (original study) | 5 mg/kg (translates to ~25 mg for 60kg human) | 3 doses on alternate days |
Interactions
Other senolytics may have additive effects on senescent cell clearance.
Different senolytic mechanisms; sequential use may be considered.
Different mechanisms; Humanin protects healthy cells while FOXO4-DRI clears senescent ones.
Quality checklist
- ✓Stored at -20°C or below
- ✓White lyophilized powder
- ✓High purity (>95%)
- ✓Clear solution after reconstitution
- !Temperature excursions may affect potency
- ×Exposed to room temperature for extended periods
- ×Discoloration
- ×Repeated freeze-thaw cycles
What to expect
Safety
- Limited human data available
- Generally well-tolerated in animal studies
- Allergic reactions
- Unexpected adverse effects
- Not yet approved for human use
- Pregnancy or breastfeeding
- Unknown safety in immunocompromised individuals
- Active cancer (theoretical - consult oncologist)
FAQ
What makes FOXO4-DRI different from other anti-aging approaches?
FOXO4-DRI is the first senolytic peptide that selectively eliminates 'zombie' senescent cells accumulating with age, whereas most anti-aging approaches target symptoms or regeneration. It disrupts FOXO4-p53 interaction in senescent cells to trigger apoptosis, effectively removing damaged cells rather than just supporting healthy ones.
Is FOXO4-DRI safe if I have a history of cancer?
FOXO4-DRI is theoretically contraindicated in active cancer due to p53 pathway modulation, though the mechanism (disrupting FOXO4-p53 interaction) differs from therapies affecting healthy p53. Cancer history requires careful medical consideration. Most sources recommend consulting an oncologist before using, especially with active malignancy.
How much FOXO4-DRI should a human dose based on mouse studies?
The original 2017 mouse study used 5 mg/kg IP, 3 times on alternate days. For a 60kg human, this translates to approximately 25mg per dose, administered as 3 doses every other day (75-100mg total per cycle). However, human pharmacokinetics differ significantly from mice, making these translations speculative.
What visible changes occurred in aged mice treated with FOXO4-DRI?
Aged mice receiving FOXO4-DRI showed restored fur density, improved physical fitness, enhanced organ function (particularly kidneys), and improved testosterone levels. These dramatic improvements suggest senescent cell clearance genuinely restored tissue homeostasis, though results in humans remain theoretical.
References
- 1An Example of Senolytic Self-Experimentation with FOXO4-DRIFight Aging! · 2017
Self-experimenters have translated the mouse protocol to ~25 mg per injection subcutaneously, 3 doses every other day, for 75-100 mg total per treatment cycle.
animalSource ↗